Aeglea BioTherapeutics, Inc. (AGLE)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 03:37PM EDT. Market open.
| Previous Close | 0.4270 |
| Open | 0.4200 |
| Bid | 0.4080 x 3000 |
| Ask | 0.4085 x 900 |
| Day's Range | 0.4010 - 0.4500 |
| 52 Week Range | 0.3720 - 8.5000 |
| Volume | |
| Avg. Volume | 668,862 |
| Market Cap | 25.313M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0940 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.67 |
- Zacks
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Zacks
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.
© 2022 Yahoo. All rights reserved.
